Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(147 productos)
- Bcr-Abl(103 productos)
- EGFR(572 productos)
- FAK(71 productos)
- FLT(91 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- JAK(246 productos)
- PDGFR(126 productos)
- RAAS(88 productos)
- Src(80 productos)
- Syk(37 productos)
- Trombina(47 productos)
- VDA(2 productos)
- VEGFR(267 productos)
Mostrar 6 subcategorías más
Se han encontrado 1483 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
GSK2646264
CAS:<p>GSK2646264 (Compound 44) inhibits SYK (pIC50=7.1) and kinases like LCK, LRRK2; penetrates skin.</p>Fórmula:C24H26N2O2Forma y color:SolidPeso molecular:374.48JNJ-17029259
CAS:<p>JNJ-17029259 is an orally selective, potent inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2).</p>Fórmula:C26H30N6OPureza:98%Forma y color:SolidPeso molecular:442.56Tubulin/JAK2-IN-1
CAS:<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Fórmula:C22H20N6O3Forma y color:SolidPeso molecular:416.43BTK-IN-11
CAS:<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Fórmula:C26H22ClN5O3Forma y color:SolidPeso molecular:487.94FGFR-IN-8
CAS:<p>FGFR-IN-8, potent oral FGFR inhibitor for wild-type/mutant types, induces apoptosis with anti-cancer properties.</p>Fórmula:C27H31Cl2N9O2Forma y color:SolidPeso molecular:584.5Famitinib malate
CAS:<p>Famitinib malate (SHR1020) is a potent oral kinase inhibitor targeting c-kit, VEGFR-2, and PDGFRβ, with IC50s 2.3, 4.7, 6.6 nM, useful for cancer research.</p>Fórmula:C27H33FN4O7Forma y color:SolidPeso molecular:544.57UNC5293
CAS:<p>UNC5293: potent oral MERTK inhibitor, Ki=190 pM, IC50=0.9 nM; selective vs Axl/Tyro3/Flt3; good mouse PK; used in leukemia research.</p>Fórmula:C30H42N6O2Forma y color:SolidPeso molecular:518.69EGFR-IN-74
<p>EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.</p>Fórmula:C32H28BrF3N6O4SForma y color:SolidPeso molecular:729.57Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Fórmula:C20H17N9Pureza:98%Forma y color:SolidPeso molecular:383.41Upadacitinib tartrate
CAS:<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Fórmula:C21H33F3N6O11Pureza:98%Forma y color:SolidPeso molecular:602.521(Rac)-PF-06250112
CAS:<p>(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.</p>Fórmula:C22H20F2N6O2Pureza:98%Forma y color:SolidPeso molecular:438.43ALK/EGFR-IN-2
CAS:<p>ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.</p>Fórmula:C27H34ClN7O3SForma y color:SolidPeso molecular:572.12BT424
CAS:BT424, a specific HCK inhibitor, modulates macrophage activation and autophagy in vitro, and mitigates inflammation and renal fibrosis in the UUO model [1].Fórmula:C22H15BCl2N2O2Pureza:98%Forma y color:SolidPeso molecular:421.08HDAC/JAK/BRD4-IN-1
CAS:<p>HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4.</p>Fórmula:C24H28N6O3Pureza:98%Forma y color:SolidPeso molecular:448.52EGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Fórmula:C36H46BrN8O2PForma y color:SolidPeso molecular:733.68FLT3/ITD-IN-5
CAS:FLT3/ITD-IN-5 (Example 6) is an orally active inhibitor of both FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is utilized in cancer research.Fórmula:C23H25N7O2Forma y color:SolidPeso molecular:431.49HIF-2α-IN-1
CAS:<p>HIF-2α-IN-1 is a potent HIF-2α inhibitor with IC50 values less than 500 nM.</p>Fórmula:C16H8F5NO4SPureza:97.99%Forma y color:SolidPeso molecular:405.3ALK/ROS1-IN-1
CAS:<p>ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).</p>Fórmula:C30H35F3N6O3Pureza:98%Forma y color:SolidPeso molecular:584.63JAK-IN-4
CAS:<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Fórmula:C18H21N4Na2O6PPureza:98%Forma y color:SolidPeso molecular:466.341JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Fórmula:C19H17N5O4Pureza:98%Forma y color:SolidPeso molecular:379.37DZD1516
CAS:<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Fórmula:C28H27F2N7O3Pureza:98%Forma y color:SolidPeso molecular:547.56CP-547632 TFA
CAS:<p>CP-547632 TFA, an oral VEGFR-2 and FGF inhibitor, IC50: VEGFR-2 at 11 nM, FGF at 9 nM, shows antitumor activity.</p>Fórmula:C22H25BrF5N5O5SPureza:98%Forma y color:SolidPeso molecular:646.43PI3K/VEGFR2-IN-1
CAS:<p>PI3K/VEGFR2-IN-1 is a potent dual inhibitor targeting both PI3K and VEGFR2 with IC50 values of 2.21 μM for PI3K and 68 μM for VEGFR2, respectively.</p>Fórmula:C17H14ClN3OSPureza:98%Forma y color:SolidPeso molecular:343.83BTK-IN-18
CAS:<p>BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.</p>Fórmula:C20H22Cl2N6OForma y color:SolidPeso molecular:433.33Sulfatinib
CAS:<p>Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC 50 s ranging from 1 to</p>Fórmula:C24H28N6O3SPureza:99.21% - >99.99%Forma y color:SolidPeso molecular:480.58MTP
CAS:<p>MTP, a PKM2 inhibitor, promotes apoptosis in cancer cells via caspase-3 activation while also inducing autophagy and enhancing ROS generation.</p>Fórmula:C29H23F3N4O2Pureza:98%Forma y color:SolidPeso molecular:516.51TAK-659
CAS:<p>TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.</p>Fórmula:C17H21FN6OPureza:98%Forma y color:SolidPeso molecular:344.39Atiprimod dimaleate
CAS:Atiprimod Dimaleate is a JAK2 inhibitor.Fórmula:C30H52N2O8Forma y color:SolidPeso molecular:568.74BPIQ-I
CAS:<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Fórmula:C16H12BrN5Forma y color:SolidPeso molecular:354.2MS 154
CAS:<p>MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.</p>Fórmula:C46H54ClFN8O8Forma y color:SolidPeso molecular:901.42Ruxolitinib sulfate
CAS:<p>Ruxolitinib sulfate, a potent JAK1/2 inhibitor (IC50: 3.3/2.8 nM), is >130x more selective for JAK1/2 than JAK3.</p>Fórmula:C17H20N6O4SForma y color:SolidPeso molecular:404.45JAK-IN-1
CAS:<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Fórmula:C20H24N6O2Pureza:98%Forma y color:SolidPeso molecular:380.44FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Fórmula:C25H26N6O2Pureza:98%Forma y color:SolidPeso molecular:442.523EGFR-IN-32
CAS:<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Fórmula:C31H34N6O3Forma y color:SolidPeso molecular:538.64HDAC-IN-63
CAS:<p>HDAC-IN-63 (Compound 63) is a dual FLT3/HDAC inhibitor with IC50 values of 0.844 nM for FLT3 and 30.0 nM for HDAC1.</p>Fórmula:C25H26Cl2N6O3Forma y color:SolidPeso molecular:529.42Irpagratinib
CAS:<p>Irpagratinib (ABSK011) is an FGFR4 antagonist with anticancer activity, inhibiting FGFR4 autophosphorylation and blocking downstream signaling pathways.</p>Fórmula:C28H32F2N6O5Pureza:99.08% - 99.38%Forma y color:SolidPeso molecular:570.59CHMFL-FLT3-122
CAS:<p>CHMFL-FLT3-122 is a potent and orally available FLT3 kinase inhibitor used to treat FLT3-ITD positive acute myeloid leukemia.</p>Fórmula:C26H29N7O2Pureza:99.63%Forma y color:SolidPeso molecular:471.55Brolucizumab
CAS:<p>Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.</p>Pureza:95%Forma y color:LiquidALK-IN-6
CAS:<p>ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).</p>Fórmula:C26H29ClD3N5O3SPureza:98%Forma y color:SolidPeso molecular:533.1TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Fórmula:C17H11ClF2N4O2Forma y color:SolidPeso molecular:376.74Pivanex
CAS:<p>Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.</p>Fórmula:C10H18O4Pureza:≥98%Forma y color:SolidPeso molecular:202.25ALK/EGFR-IN-1
CAS:<p>ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.</p>Fórmula:C27H34ClN7O3SPureza:98%Forma y color:SolidPeso molecular:572.12Nazartinib S-enantiomer
CAS:<p>Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.</p>Fórmula:C26H31ClN6O2Pureza:98%Forma y color:SolidPeso molecular:495.02YS-363
CAS:<p>YS-363 is a potent, selective, and orally active inhibitor of the epidermal growth factor receptor (EGFR), exhibiting half-maximal inhibitory concentrations (</p>Fórmula:C30H30N4O3Pureza:98%Forma y color:SolidPeso molecular:494.58AT-9283 L-lactate
CAS:<p>AT-9283 L-lactate is an inhibitor of aurora kinase.</p>Fórmula:C22H29N7O5Pureza:98%Forma y color:SolidPeso molecular:471.52Nezulcitinib
CAS:<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Fórmula:C30H37N7O2Forma y color:SolidPeso molecular:527.66BTK inhibitor 20
CAS:<p>BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .</p>Fórmula:C37H42N8O4Forma y color:SolidPeso molecular:662.78KB SRC 4
CAS:KB SRC 4 is a selective and potent c-Src inhibitor with antitumour activity that inhibits the growth of cancer cells.CAS 번호13460-73-83-4Fórmula:C32H23ClN8Pureza:98.83% - 99.34%Forma y color:SolidPeso molecular:555.03HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Fórmula:C27H33N7O3Forma y color:SolidPeso molecular:503.6TIE-2/VEGFR-2 kinase-IN-4
CAS:<p>TIE-2/VEGFR-2 kinase-IN-4, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting inhibitory</p>Fórmula:C26H17F4N5O4Forma y color:SolidPeso molecular:539.44Infigratinib-Boc
CAS:<p>Infigratinib-Boc, a derivative of the ATP-competitive pan-FGFR inhibitor Infigratinib, incorporates a Boc (t-Butyloxy carbonyl) group [1].</p>Fórmula:C29H35Cl2N7O5Forma y color:SolidPeso molecular:632.54BTK-IN-19
CAS:<p>BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .</p>Fórmula:C21H22Cl2N6OForma y color:SolidPeso molecular:445.35DW10075
CAS:<p>DW10075, a novel potent and highly selective inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.</p>Fórmula:C29H23N5O3Forma y color:SolidPeso molecular:489.52CCT365623 hydrochloride
CAS:<p>CCT365623 hydrochloride is an orally active inhibitor of lysyl oxidase (LOX) (IC50: 0.89 μM). It suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF.</p>Fórmula:C18H18ClNO4S3Pureza:98%Forma y color:SolidPeso molecular:443.99FC 11
CAS:<p>FC 11 is a reversible FAK PROTAC Degrader with DC50 of 40-370 pM and degrades pFAKtyr397 in TM3 cells within 3 hours at 100 nM.</p>Fórmula:C41H42F3N13O9SForma y color:SolidPeso molecular:949.91CT-721
CAS:<p>CT-721: potent, time-bound Bcr-Abl inhibitor, IC50 21.3 nM, effective against CML.</p>Fórmula:C30H29ClN6OPureza:98%Forma y color:SolidPeso molecular:525.04(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Fórmula:C16H14N2O2Forma y color:SolidPeso molecular:266.29TIE-2/VEGFR-2 kinase-IN-5
CAS:TIE-2/VEGFR-2 kinase-IN-5 is a TIE-2 and VEGFR-2 tyrosine kinase receptor inhibitor commonly used in biomedical research related to angiogenesis.Fórmula:C21H13F6N5O2Pureza:99.79%Forma y color:SolidPeso molecular:481.35BMS-935177
CAS:<p>BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.</p>Fórmula:C31H26N4O3Pureza:99.89%Forma y color:SolidPeso molecular:502.56Sevabertinib
CAS:<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Fórmula:C24H25ClN4O5Pureza:99.81%Forma y color:SolidPeso molecular:484.93Ifebemtinib
CAS:Ifebemtinib (BI-853520) is an adhesion plaque kinase inhibitor with anti-tumour activity for the study of breast cancer.Fórmula:C28H28F4N6O4Pureza:98.84% - 99.85%Forma y color:SolidPeso molecular:588.55EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Fórmula:C28H33N7O2Pureza:98.64%Forma y color:SolidPeso molecular:499.61IN-1130
CAS:<p>IN-1130: ALK5 inhibitor, IC50 - 5.3 nM (Smad3), 36 nM (casein), 4.3 μM (p38α MAPK).</p>Fórmula:C25H20N6OPureza:99.79%Forma y color:SolidPeso molecular:420.47Zongertinib
CAS:<p>Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (</p>Fórmula:C29H29N9O2Pureza:98.24%Forma y color:SolidPeso molecular:535.6KER047
CAS:ALK2-IN-4, a highly effective ALK2 inhibitor.Fórmula:C26H30FN7OPureza:98.49% - >99.99%Forma y color:SolidPeso molecular:475.56Src Inhibitor 3
CAS:Src Inhibitor 3 blocks c-Src kinase (IC50 <3 nM CSK HTRF, <4 nM Caliper), boosting T cell growth from receptor signals.Fórmula:C34H32ClFN8O4Pureza:98.35%Forma y color:SolidPeso molecular:671.12HM43239
CAS:<p>HM43239: oral FLT3 inhibitor; IC50: FLT3 WT 1.1nM, ITD 1.8nM, D835Y 1.0nM; blocks p-STAT5/p-ERK; affects SYK, JAK1/2, TAK1; halts leukemia cell growth.</p>Fórmula:C29H33ClN6Pureza:99.7%Forma y color:SolidPeso molecular:501.07Dual Cathepsin L/JAK-IN-1
CAS:<p>DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).</p>Fórmula:C19H18ClN5Forma y color:SolidPeso molecular:351.833TTT 3002
CAS:<p>TTT 3002: oral FLT3 inhibitor for AML research, blocks D835 mutations, potent at 0.2 nM IC50.</p>Fórmula:C27H23N5O3Forma y color:SolidPeso molecular:465.50JAK2 JH2 binder-1
CAS:<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Fórmula:C29H25N7O6SForma y color:SolidPeso molecular:599.62EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Fórmula:C33H28N6O3SForma y color:SolidPeso molecular:588.68EGFR-IN-62
<p>EGFR-IN-62: IC50 of 10-242 nM for various EGFR mutations, blocks A549/H1975 cell cycle, induces apoptosis, and inhibits cell motility and proliferation.</p>Fórmula:C30H33N9O2Forma y color:SolidPeso molecular:551.64PF-06463922 acetate
CAS:<p>PF-06463922 acetate: ALK/ROS1 inhibitor, brain- penetrable, active vs crizotinib-resistant mutants, in NSCLC trials.</p>Fórmula:C23H23FN6O4Forma y color:SolidPeso molecular:466.46FGFR1 inhibitor-6
<p>FGFR1 inhibitor-6, IC50: 16.31 nM, blocks cell cycle at pro-G1/G2/M and induces apoptosis.</p>Fórmula:C27H19N5O4S2Forma y color:SolidPeso molecular:541.6ALK-IN-23
<p>ALK-IN-23 inhibits ALK (IC50: 1.6-0.71 nM), hinders cancer cell spread, forms colonies in vitro, and reduces tumors in mice with low toxicity.</p>Fórmula:C26H29ClN8O3SForma y color:SolidPeso molecular:569.08BTK-IN-10
CAS:<p>BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).</p>Fórmula:C25H24F2N4O2Forma y color:SolidPeso molecular:450.48VEGFR-2-IN-14
<p>VEGFR-2-IN-14 (Compound 5) is a potent inhibitor of VEGFR-2, which inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.</p>Fórmula:C24H23N3O3SForma y color:SolidPeso molecular:433.52NSC381467
CAS:<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C20H16O7Forma y color:SolidPeso molecular:368.34AZD0424
CAS:<p>AZD0424: oral Src/Abl kinase inhibitor; potential anticancer; induces apoptosis, cell cycle arrest in lymphoma.</p>Fórmula:C25H29ClN6O5Pureza:98%Forma y color:SolidPeso molecular:528.99EGFR-IN-3
EGFR-IN-3 is an EGFR inhibitor with antitumor activity.EGFR-IN-3 inhibits EGFRwt-TK, induces apoptosis (cell death), and can block cells in the G2/M phase.Fórmula:C24H18F4N6O2SPureza:98.1%Forma y color:SolidPeso molecular:530.5JP-153
CAS:<p>JP-153 is an inhibitor of Src-FAK-Paxillin signaling. It suppresses Src-dependent phosphorylation of paxillin (Y118) and subsequent activation of Akt (S473). JP-153 reduces VEGF-induced migration and proliferation of retinal endothelial cells and is applicable in the study of neovascular eye diseases.</p>Fórmula:C21H19NO5Forma y color:SolidPeso molecular:365.379Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Fórmula:C18H20F6N4OForma y color:SolidPeso molecular:422.37VVD-118313
CAS:<p>VVD-118313 (5a) is a potent JAK1 inhibitor targeting allosteric cysteine, blocking cytokine signaling for cancer research.</p>Fórmula:C19H22Cl2N2O3SForma y color:SolidPeso molecular:429.36FAK-IN-26
CAS:<p>FAK-IN-26 is a blood-brain barrier-penetrating inhibitor of Focal Adhesion Kinase (FAK) with an IC50 of 0.87 nM. It significantly reduces tumor cell viability, cancer stem cell activity, and cell migration in A549 and SKOV-3 cell lines. FAK-IN-26 exhibits potent anticancer activity, achieving tumor inhibition rates of 59.15% and 57.9% in A549 and SKOV-3 tumor mouse models, respectively.</p>Fórmula:C20H19BrFN5O2Forma y color:SolidPeso molecular:460.30VEGFR-2-IN-26
CAS:<p>VEGFR-2-IN-26 inhibits VEGFR-2 (IC50: 15.5 nM), combating various cancers' cell growth.</p>Fórmula:C24H19F3N6O2Forma y color:SolidPeso molecular:480.44Protein kinase inhibitor 11
CAS:<p>Protein kinase inhibitor 11 (Compound I-96) is an agent that inhibits the activity of PIM-1, CDK-2, GSK-3, and SRC. It shows potential for research in cancer, autoimmune diseases, and neurodegenerative disorders.</p>Fórmula:C21H18FN5O2SForma y color:SolidPeso molecular:423.463FGFR3-IN-4
CAS:<p>FGFR3-IN-4 is a selective inhibitor targeting FGFR3, demonstrating an IC50 value of under 50 nM.</p>Fórmula:C26H24ClN7OForma y color:SolidPeso molecular:485.97JAK-IN-19
<p>JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).</p>Fórmula:C26H36FN5O2Forma y color:SolidPeso molecular:469.59ERBB agonist-1
CAS:<p>ERBB agonist-1 (Compound EF-1) is an ERBB4 agonist that activates the ERBB4 signaling pathway by inducing ERBB4 receptor dimerization, with an EC50 of 10.5 μM. It promotes phosphorylation of Akt and ERK1/2, reduces collagen expression in cardiac fibroblasts, and inhibits H2O2-induced cardiomyocyte death and Ang II-induced cardiac hypertrophy. Furthermore, ERBB agonist-1 can prevent myocardial fibrosis and demonstrates cardioprotective effects in mouse models.</p>Fórmula:C24H25N3O2SForma y color:SolidPeso molecular:419.539EGFR/HER2-IN-5
<p>EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.</p>Forma y color:SolidVEGFR-2-IN-11
<p>VEGFR-2-IN-11 is a potent inhibitor of VEGFR-2 (IC50: 60.27 nM) with an IC50 value of 60.27 nM, which induces apoptosis and has anticancer activity.</p>Fórmula:C29H22BrN5SForma y color:SolidPeso molecular:552.49EGFR-IN-23
CAS:<p>EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.</p>Fórmula:C36H44BrN10O3PForma y color:SolidPeso molecular:775.68EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Fórmula:C14H11BrN4O2SForma y color:SolidPeso molecular:379.23W23-1006
CAS:<p>W23-1006 is a selective covalent ALKBH5 inhibitor. It binds to the ALKBH5 C200 residue with an IC50 value of 3.848 μM. The inhibitory activity of W23-1006 is approximately 30 times stronger than that of FTO and 8 times greater than that of ALKBH3. W23-1006 is applicable for research in triple-negative breast cancer (TNBC).</p>Fórmula:C17H12BrN3O5Forma y color:SolidPeso molecular:418.198Multi-kinase-IN-1
CAS:<p>Multi-kinase-IN-1, a powerful kinase inhibitor, exhibits antitumor properties by inducing cell apoptosis.</p>Fórmula:C35H36F2N6O6SForma y color:SolidPeso molecular:706.76JAK3/BTK-IN-3
CAS:<p>JAK3/BTK-IN-3: strong dual JAK3/BTK suppressor, promising for autoimmune disease research.</p>Fórmula:C22H28N8OForma y color:SolidPeso molecular:420.51OXA-11
CAS:OXA-11 (FAK-IN-16) is a FAK inhibitor with anti-tumor activity, useful for cancer research.Fórmula:C37H49F3N7O5PPureza:98.70% - 99.20%Forma y color:SolidPeso molecular:759.8BTK inhibitor 18
<p>BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.</p>Fórmula:C29H25N5O4S2Forma y color:SolidPeso molecular:571.67JAK1-IN-9
CAS:<p>JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.</p>Fórmula:C16H13IN6Forma y color:SolidPeso molecular:416.22AFP464 free base
CAS:<p>AFP464 (NSC710464) free base is an active HIF-1α inhibitor (IC50: 0.25 μM) and a potent aryl hydrocarbon receptor (AhR) activator.</p>Fórmula:C22H23F3N4O3Pureza:98%Forma y color:SolidPeso molecular:448.44
